Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 5Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 1476Neoplasms 999Colorectal Neoplasms 830Carcinoma, Non-Small-Cell Lung 724Carcinoma, Hepatocellular 683Stomach Neoplasms 647Lung Neoplasms 584Prostatic Neoplasms 543Pancreatic Neoplasms 456Rectal Neoplasms 338Uterine Cervical Neoplasms 303Colonic Neoplasms 295Neoplasm Metastasis 292Ovarian Neoplasms 285Esophageal Neoplasms 279Recurrence 278Leukemia, Myeloid, Acute 253Head and Neck Neoplasms 241Multiple Myeloma 232Brain Neoplasms 204Polycystic Ovary Syndrome 200Nasopharyngeal Carcinoma 198Melanoma 198Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Urinary Bladder Neoplasms 193Lymphoma 178Liver Neoplasms 178Endometrial Neoplasms 159Motor Activity 147Lymphoma, Large B-Cell, Diffuse 141

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × OTHER × Borderline Resectable Pancreatic Cancer × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04855331 2023-05-09

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Fudan University

Phase NA Unknown
120 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Fudan University

Phase 3 Unknown
300 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡